Product Specification
| Host |
Rabbit |
| Antigen |
Vimentin |
| Immunogen |
Synthetic Peptide |
| Accession |
P08670 |
| Clone Number |
SDT-029-20 |
| Antibody Type |
Rabbit mAb |
| Isotype |
IgG |
| Application |
WB, IHC-P, ICC, IF |
| Reactivity |
Hu, Ms, Rt |
| Predicted Reactivity |
Pr, Bv, Cz, Pg, Hm, Av |
| Purification |
Protein A |
| Research Area |
Neuroscience |
| Concentration |
1 mg/ml |
| Molecular Weight |
56kDa |
| Conjugation |
Unconjugated |
| Physical Appearance |
Liquid |
| Storage Buffer |
PBS, 40% Glycerol, 0.05%BSA, 0.03% Proclin 300 |
| Stability & Storage |
12 months from date of receipt / reconstitution, -20 °C as supplied |
Dilution
| application |
dilution |
species |
| WB |
1:1000 |
|
| IHC-P |
1:1000 |
|
| ICC |
1:200 |
|
| IF |
1:200 |
|
Background
Vimentin is a structural protein that in humans is encoded by the VIM gene. Vimentin is a type III intermediate filament (IF) protein that is expressed in mesenchymal cells. IF proteins are found in all animal cells as well as bacteria. Intermediate filaments, along with tubulin-based microtubules and actin-based microfilaments, comprises the cytoskeleton. All IF proteins are expressed in a highly developmentally-regulated fashion; vimentin is the major cytoskeletal component of mesenchymal cells. Because of this, vimentin is often used as a marker of mesenchymally-derived cells or cells undergoing an epithelial-to-mesenchymal transition (EMT) during both normal development and metastatic progression.